Oncolytics Biotech (Oncolytics Biotech) Equity-to-Asset : 0.71 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Oncolytics Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $20.55 Mil. Oncolytics Biotech's Total Assets for the quarter that ended in Dec. 2023 was $28.94 Mil.

The historical rank and industry rank for Oncolytics Biotech's Equity-to-Asset or its related term are showing as below:

ONCY' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.01 Med: 0.72 Max: 0.9
Current: 0.71

During the past 13 years, the highest Equity to Asset Ratio of Oncolytics Biotech was 0.90. The lowest was -0.01. And the median was 0.72.

ONCY's Equity-to-Asset is ranked better than
55.72% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs ONCY: 0.71

Oncolytics Biotech Equity-to-Asset Historical Data

The historical data trend for Oncolytics Biotech's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Equity-to-Asset Chart

Oncolytics Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

-0.01

0.72

0.79

0.71

Oncolytics Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.71	0.73	0.70	0.63	0.71

Competitive Comparison of Oncolytics Biotech's Equity-to-Asset

For the Biotechnology subindustry, Oncolytics Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncolytics Biotech's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Equity-to-Asset falls into.

Oncolytics Biotech Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Oncolytics Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	20.545	/	28.936
	=

Oncolytics Biotech's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	20.545	/	28.936
	=

Oncolytics Biotech (NAS:ONCY) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Oncolytics Biotech Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech (Oncolytics Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

ONC:Canada

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.